US · Healthcare · Biotechnology
EPS came in at -1.71 against a street estimate of -1.08 — a miss of 58.3%.
Analysts rate Abivax SA American Depositary Shares a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $164.00.
| Fund | Stake |
|---|---|
| TCG Crossover Management, LLC | 6.88% |
| Darwin Global Management, Ltd. | 4.15% |
| Helikon Investments Ltd | 3.19% |
| Vestal Point Capital LP | 2.69% |
| Jupiter Topco LLC | 2.19% |
| UBS Group AG | 2.11% |
| ADAR1 Capital Management LLC | 2.07% |
| Morgan Stanley - Brokerage Accounts | 1.95% |
| Document | Date |
|---|---|
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Abivax reported a first-half 2026 net loss of €165.9 million, compared with €100.8 million in the first half of 2025. • Operating | 2026-09-21 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Abivax plans to issue and sell 6,400,000 American Depositary Shares (ADSs), with each ADS representing one ordinary share. • Unde | 2026-07-02 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • Abivax reported positive results from ABTECT Maintenance Part 2, evaluating obefazimod in adults with moderately to severely activ | 2026-06-29 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • Abivax reported positive topline results from the Phase 3 ABTECT 44-week maintenance trial of once-daily oral obefazimod in modera | 2026-06-02 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Abivax is a clinical-stage biopharmaceutical company reporting under IFRS in euros. • The company had 78,536,412 ordinary shares | 2026-03-23 |
| Quarterly results (6-K) · Q4 2025 HEADLINE NUMBERS • Abivax reported a 2025 net loss of €336.1 million, compared with €176.2 million in 2024. • Operating loss increased to €246.1 mil | 2026-03-23 |
| Annual report FY2024 (20-F) | 2025-03-24 |
| Quarterly results (6-K) · Q2 2024 | 2024-09-09 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Abivax SA American Depositary Shares — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.